Synthroid information from trusted sources:
SYNTHROID (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C15H10I4N NaO4&bull, H2O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:Acacia, confectioner's sugar (contains corn starch), lactose monohydrate, magnesium stearate, povidone, and talc. The following are the color additives by tablet strength:Meets USP Dissolution Test 3... ... Levothyroxine sodium is used for the following indications:...
WARNING: Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Levothyroxine is used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. Levothyroxine injection can be used as a substitute for the oral dose when a rapid effect is needed and when the oral route is not allowed .
Levothyroxine, a synthetic thyroid hormone, may be given in any of the following cases:
Levothyroxine, a thyroid hormone, is used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. Without this hormone, the body cannot function properly, resulting in poor growth, slow speech, lack of energy, weight gain, hair loss, dry thick skin, and increased sensitivity to cold. When taken correctly, levothyroxine reverses these symptoms. Levothyroxine is also used to treat congenital hypothyroidism (cretinism) and goiter (enlarged thyroid gland).
Caution should be exercised when the following drugs are administered concomitantly with SINEMET CR (Carbidopa-Levodopa) Sustained-Release.
In controlled clinical trials, patients predominantly with moderate to severe motor fluctuations while on SINEMET (Carbidopa-Levodopa) were randomized to therapy with either SINEMET (Carbidopa-Levodopa) or SINEMET CR. The adverse experience frequency profile of SINEMET CR did not differ substantially from that of SINEMET (Carbidopa-Levodopa), as shown in Table I.